Heiko Schoder

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer
    Heiko Schoder
    Department of Radiology, Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mol Imaging Biol 14:245-51. 2012
  2. ncbi CT in PET/CT: essential features of interpretation
    Heiko Schoder
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 46:1249-51. 2005
  3. ncbi Fundamentals of molecular imaging: rationale and applications with relevance for radiation oncology
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Nucl Med 38:119-28. 2008
  4. ncbi 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI
    Heiko Schoder
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 47:755-62. 2006
  5. ncbi PET imaging for response assessment in lymphoma: potential and limitations
    Heiko Schoder
    Department of Radiology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 1305 York Avenue, New York, NY 10021, USA
    Radiol Clin North Am 46:225-41, viii. 2008
  6. ncbi 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:4761-9. 2005
  7. ncbi PET monitoring of therapy response in head and neck squamous cell carcinoma
    Heiko Schoder
    Department of Radiology, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 50:74S-88S. 2009
  8. ncbi Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma
    Heiko Schoder
    Memorial Sloan Kettering Cancer Center, Department of Radiology, Nuclear Medicine Service, Box 77, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:4643-51. 2005
  9. ncbi Screening for cancer with PET and PET/CT: potential and limitations
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 48:4S-18S. 2007
  10. ncbi PET/CT: a new imaging technology in nuclear medicine
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 77, New York, NY 10021, USA
    Eur J Nucl Med Mol Imaging 30:1419-37. 2003

Detail Information

Publications71

  1. ncbi Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer
    Heiko Schoder
    Department of Radiology, Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mol Imaging Biol 14:245-51. 2012
    ..To investigate the utility of (11)C-acetate positron emission tomography/computed tomography (PET/CT) for staging of bladder cancer and response assessment after neoadjuvant chemotherapy...
  2. ncbi CT in PET/CT: essential features of interpretation
    Heiko Schoder
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 46:1249-51. 2005
  3. ncbi Fundamentals of molecular imaging: rationale and applications with relevance for radiation oncology
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Nucl Med 38:119-28. 2008
    ..In contrast, this article will focus on the biochemical principles of cancer metabolism that provide the rationale for positron emission tomography imaging in radiation oncology...
  4. ncbi 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI
    Heiko Schoder
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 47:755-62. 2006
    ..In particular, the value of combined PET/CT has not been determined in this group of patients...
  5. ncbi PET imaging for response assessment in lymphoma: potential and limitations
    Heiko Schoder
    Department of Radiology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 1305 York Avenue, New York, NY 10021, USA
    Radiol Clin North Am 46:225-41, viii. 2008
    ..Until the results of ongoing clinical trials emerge over the next 5 years, interim PET should be considered investigational and should not be used for patient management outside of study protocols...
  6. ncbi 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:4761-9. 2005
    ..We calculated sensitivity and specificity of PET and correlated PET findings with PSA values, other clinical parameters, and conventional imaging, when available...
  7. ncbi PET monitoring of therapy response in head and neck squamous cell carcinoma
    Heiko Schoder
    Department of Radiology, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 50:74S-88S. 2009
    ....
  8. ncbi Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma
    Heiko Schoder
    Memorial Sloan Kettering Cancer Center, Department of Radiology, Nuclear Medicine Service, Box 77, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:4643-51. 2005
    ..18)Fluorodeoxyglucose positron emission tomography (FDG PET) is widely used for the staging of lymphoma. We investigated whether the intensity of tumor FDG uptake could differentiate between indolent and aggressive disease...
  9. ncbi Screening for cancer with PET and PET/CT: potential and limitations
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 48:4S-18S. 2007
    ..Researchers should also investigate the utility of whole-body PET/CT for the surveillance of selected groups of patients who have cancer, who have completed curative treatment, but who remain at high risk for recurrent disease...
  10. ncbi PET/CT: a new imaging technology in nuclear medicine
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 77, New York, NY 10021, USA
    Eur J Nucl Med Mol Imaging 30:1419-37. 2003
    ....
  11. ncbi Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 45:559-66. 2004
    ..Previous studies suggested that measurements of (18)F-FDG accumulation in tissue might be affected by the image reconstruction method, but the clinical relevance of these findings has not been assessed...
  12. ncbi Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion
    Heiko Schoder
    Department of Radiology, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, Box 77, 1275 York Ave, New York, NY 10021, USA
    Radiology 231:65-72. 2004
    ..To compare diagnostic accuracy of attenuation-corrected positron emission tomography (PET) with fused PET and computed tomography (CT) in patients with head and neck cancer and to evaluate the effect of PET/CT findings on patient care...
  13. ncbi Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET
    Jacobus F A Jansen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Int J Radiat Oncol Biol Phys 82:299-307. 2012
    ..Additionally, pretreatment multimodality imaging was evaluated for its efficacy in predicting short-term response to treatment...
  14. ncbi Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer
    Seng Chuan Ong
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 49:532-40. 2008
    ..We investigated the clinical utility of 18F-FDG PET/CT in this setting...
  15. ncbi Deep-inspiration breath-hold PET/CT: clinical findings with a new technique for detection and characterization of thoracic lesions
    Gustavo S P Meirelles
    Department of Radiology, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 48:712-9. 2007
    ..Our aim was to compare the detection and characterization of thoracic lesions on PET/CT with and without a deep-inspiration protocol...
  16. ncbi Evaluation of different methods of 18F-FDG-PET target volume delineation in the radiotherapy of head and neck cancer
    Carlo Greco
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Clin Oncol 31:439-45. 2008
    ..To quantify differences between the alternative methods of F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)-based delineation of the gross tumor volume in patients with head and neck cancer...
  17. ncbi Reduction of respiratory motion artifacts in PET imaging of lung cancer by respiratory correlated dynamic PET: methodology and comparison with respiratory gated PET
    Sadek A Nehmeh
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 44:1644-8. 2003
    ..Both methods provide the ability to correct for motion artifacts and more accurately quantitate radiotracer uptake within lung lesions. Both methods were evaluated in phantom studies and 1 patient...
  18. ncbi PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies
    Heiko Schoder
    Department of Radiology, Nuclear Medicine Service, and Gerschel PET Center, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:72S-81S. 2004
    ..This article summarizes preliminary data of PET/CT studies and highlights potential clinical applications for PET/CT, with particular emphasis on lymphoma, melanoma and gastrointestinal tumors...
  19. ncbi The CT motion quantitation of lung lesions and its impact on PET-measured SUVs
    Yusuf E Erdi
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:1287-92. 2004
    ..Therefore, an incongruent lesion position during CT acquisition will bias activity estimates using PET. In this study, we systematically analyzed the range of activity concentration changes, hence SUV, for lung lesions...
  20. ncbi Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer
    Gustavo S P Meirelles
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 16:6093-9. 2010
    ..To compare the diagnostic and prognostic value of [(18)F] fluorodeoxyglucose positron emission tomography (FDG-PET) and bone scans (BS) in the assessment of osseous lesions in patients with progressing prostate cancer...
  21. ncbi Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases
    Jacobus F A Jansen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 77:1403-10. 2010
    ....
  22. ncbi Positron emission imaging of head and neck cancer, including thyroid carcinoma
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Nucl Med 34:180-97. 2004
    ..Although diffuse FDG uptake usually indicates thyroiditis, focal uptake has been related to thyroid cancer in 25-50% of cases and should therefore be evaluated further if a proven malignancy would cause a change in patient management...
  23. ncbi Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer
    Elizabeth R Dennis
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 30:519-24. 2012
    ..Prior studies have shown the prognostic value of a baseline BSI. This study tested whether treatment-related changes in BSI are prognostic for survival and compared BSI to prostate-specific antigen (PSA) as an outcome measure...
  24. ncbi Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy
    Nancy Lee
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 75:101-8. 2009
    ....
  25. ncbi The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer
    Ravinder K Grewal
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Nucl Med 51:1361-7. 2010
    ..We performed planar imaging and SPECT/CT in a consecutive series of patients after (131)I therapy...
  26. ncbi Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels
    Seng C Ong
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 48:501-7. 2007
    ..The role of (18)F-FDG PET in MTC remains somewhat unclear. We reviewed our own experience with (18)F-FDG PET in postthyroidectomy MTC patients with elevated calcitonin...
  27. ncbi Deep-inspiration breath-hold PET/CT of the thorax
    Sadek A Nehmeh
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 48:22-6. 2007
    ..This article presents particular emphasis on the technical aspects required for clinical implementation...
  28. ncbi 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions
    Amit Singnurkar
    Department of Radiology Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 51:1833-40. 2010
    ..The utility of (18)F-FDG PET/CT for response assessment in malignant lung tumors treated with radiofrequency ablation (RFA) and for the detection and prediction of local recurrence was investigated...
  29. ncbi Advances in oncologic imaging: update on 5 common cancers
    Oguz Akin
    Weill Medical College of Cornell University, Memorial Hospital for Cancer and Allied Diseases, New York, NY, USA
    CA Cancer J Clin 62:364-93. 2012
    ..This article provides updates on the latest approaches to imaging of 5 common cancers: breast, lung, prostate, and colorectal cancers, and lymphoma...
  30. ncbi 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma
    Remy Lim
    Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 53:1506-13. 2012
    ..We investigated the prognostic value of staging (18)F-FDG PET/CT, beyond clinical risk factors, for predicting DM and OS in 176 patients after definitive chemoradiotherapy...
  31. ncbi Positron emission tomography for prostate, bladder, and renal cancer
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Nucl Med 34:274-92. 2004
    ..Bladder cancer imaging with 11C choline, 11C methionine, or 11C- acetate deserves further study...
  32. ncbi Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT
    Josef J Fox
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 52:1727-32. 2011
    ..We propose a standardized approach to quantitative molecular imaging (MI) in cancer patients with multiple lesions...
  33. ncbi The current status of positron-emission tomography scanning in the evaluation and follow-up of patients with head and neck cancer
    David I Kutler
    Division of Head and Neck Surgery, Department of Otolaryngology, New York University Medical Center, New York, NewYork 10021, USA
    Curr Opin Otolaryngol Head Neck Surg 14:73-81. 2006
    ..In particular, its clinical value in the evaluation of the unknown primary, and the evaluation of recurrent or residual disease, is well established and has shown to be more accurate than conventional imaging modalities...
  34. ncbi Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer
    Wenli Wang
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 51:37-45. 2010
    ....
  35. ncbi Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
    Lale Kostakoglu
    Mount Sinai School of Medicine, New York, NY, USA
    Leuk Lymphoma 53:2143-50. 2012
    ..The combined analysis of PET-2 with dCT-2 suggested a better predictive value for PFS compared to either test alone. Further studies are under way to confirm these findings...
  36. ncbi Target volume delineation in oropharyngeal cancer: impact of PET, MRI, and physical examination
    Anuradha Thiagarajan
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 83:220-7. 2012
    ..This study aims to evaluate contributions of magnetic resonance imaging (MRI), positron emission tomography (PET), and physical examination (PE) to GTV delineation in oropharyngeal cancer (OPC)...
  37. ncbi Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma
    Michael Rivera
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 113:48-56. 2008
    ..However, to the authors' knowledge, the histology of FDG-PET-positive RAIR metastatic thyroid carcinoma has not been described to date...
  38. ncbi Thymic extension in the superior mediastinum in patients with thymic hyperplasia: potential cause of false-positive findings on 18F-FDG PET/CT
    Clare S Smith
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    AJR Am J Roentgenol 188:1716-21. 2007
    ..In light of the increasing clinical use of FDG PET/CT for cancer imaging, it is important that nuclear medicine physicians and radiologists be aware of this phenomenon to avoid misdiagnosis or overstaging of disease...
  39. ncbi Molecular targeting of the lymphovascular system for imaging and therapy
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Metastasis Rev 25:185-201. 2006
    ..We also review the current status of sentinel lymph node mapping with radiocolloids and the application of molecular targeting for the development of a radiopharmaceutical specifically designed for sentinel lymph node mapping...
  40. ncbi Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study
    Nancy Y Lee
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 70:2-13. 2008
    ....
  41. ncbi Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET
    Neeta Pandit-Taskar
    Department of Radiology, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    AJR Am J Roentgenol 183:1143-7. 2004
    ..7%) were malignant. Therefore, although rare, unexplained focal abdominal FDG uptake should not be ignored and further diagnostic workup is warranted...
  42. ncbi Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma
    Craig H Moskowitz
    Departments of Medicine, Radiology, Pathology, and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 28:1896-903. 2010
    ..Outside of a clinical trial, we recommend biopsy confirmation of an abnormal interim FDG-PET scan before changing therapy...
  43. ncbi Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography studies in cancer patients
    Henry W D Yeung
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mol Imaging Biol 7:229-35. 2005
    ..We have investigated to what degree this new technique might affect the interpretation of PET images in a nonselected group of consecutive cancer patients, reflecting routine condition in a busy cancer center...
  44. ncbi PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools
    Michelle L Klem
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Pediatr Hematol Oncol 29:9-14. 2007
    ..Complete staging of rhabdomyosarcoma is critical to deliver appropriate therapy. We evaluated the role of F-fluorodeoxyglucose positron emission tomography (PET) in the staging of patients with rhabdomyosarcoma...
  45. ncbi FDG-PET detected thyroid incidentalomas: need for further investigation?
    Chandrakanth Are
    Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, 1233 York Avenue, 16 I, New York, New York, 10021, USA
    Ann Surg Oncol 14:239-47. 2007
    ..Incidental thyroid abnormalities are increasingly detected in patients undergoing PET scans. The aim of this study was to review our experience with the management of PET detected thyroid incidentalomas in a large single institution series...
  46. ncbi Molecular imaging of prostate cancer
    Josef J Fox
    Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Curr Opin Urol 22:320-7. 2012
    ..Molecular imaging with positron emission tomography (PET) is poised to fill this unmet need through noninvasive probing of the multiple molecular and cellular processes that are active in prostate cancer patients...
  47. ncbi Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients
    Daniel A Pryma
    Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 47:1260-6. 2006
    ..However, there is limited information with regard to the true diagnostic accuracy and prognostic value of 18F-FDG PET in this disease...
  48. ncbi Positron emission tomography/computerized tomography functional imaging of esophageal and colorectal cancer
    Steven M Larson
    Department of Radiology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer J 10:243-50. 2004
    ..The addition of CT to the PET imaging, causes a significant reduction in uncertainty of image interpretation and improves the distinction between benign and malignant causes for FDG-PET positive sites...
  49. ncbi Developing imaging strategies for castration resistant prostate cancer
    Josef J Fox
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Acta Oncol 50:39-48. 2011
    ..The development and use of analytically valid imaging biomarkers will increase the likelihood of clinical qualification, and ultimately lead to improved patient outcomes...
  50. ncbi [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies
    Stephanie A Terezakis
    Department of Radiation Oncology Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Int J Radiat Oncol Biol Phys 81:615-22. 2011
    ..This study examines the effects of coregistering FDG-PET and computed tomography (CT) (PET/CT) scans on treatment planning for lymphoma patients...
  51. ncbi Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET
    Henry W D Yeung
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 44:1789-96. 2003
    ..The goal of this study was to characterize this normal variant of (18)F-FDG uptake in terms of incidence and characteristic extent...
  52. ncbi A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer
    Elizabeth Smyth
    Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, New York, USA
    Cancer 118:5481-8. 2012
    ....
  53. ncbi Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
    Craig H Moskowitz
    Lymphoma Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 119:1665-70. 2012
    ..6% for patients with a positive scan (P < .001). This prospective study provides evidence that the goal of SLT in patients with Hodgkin lymphoma should be a negative FDG-PET scan before HDT/ASCT...
  54. ncbi Characterization of T-cell lymphomas by FDG PET/CT
    John Feeney
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    AJR Am J Roentgenol 195:333-40. 2010
    ....
  55. ncbi An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma
    Craig H Moskowitz
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Natl Compr Canc Netw 8:347-52. 2010
    ....
  56. ncbi Incidental breast lesions identified by 18F-fluorodeoxyglucose-positron emission tomography
    Alice Chung
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 17:2119-25. 2010
    ..We describe our experience with breast incidentalomas in a large series of PET scans performed for patients without a known history of breast cancer...
  57. ncbi Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET
    Bradley J Beattie
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 51:183-92. 2010
    ....
  58. ncbi Treadmill exercise inducing mild to moderate ischemia has no significant effect on skeletal muscle or cardiac 18F-FDG uptake and image quality on subsequent whole-body PET scan
    Ashima Lyall
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 53:917-21. 2012
    ..Thus, treadmill exercise does not affect muscle (18)F-FDG uptake or image quality on subsequent PET. Cardiac (18)F-FDG uptake on torso PET scans is unrelated to myocardial perfusion status...
  59. ncbi Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET
    David J Straus
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Blood 117:5314-20. 2011
    ..0001). Although the CR rate and PFS were lower than anticipated, patients with favorable prognostic features had a low rate of relapse. Cycle 2 PET and cycle 6 PET were predictive of PFS...
  60. ncbi I-131 uptake demonstrated in the appendix on a posttreatment scan in a patient with thyroid cancer
    Sunita Borkar
    Department of Radiology, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Nucl Med 33:551-2. 2008
  61. ncbi Effect of respiratory gating on quantifying PET images of lung cancer
    Sadek A Nehmeh
    Department of Medical Physics, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 43:876-81. 2002
    ..We have developed a new technique to gate lung 18F-FDG PET images in synchronization with the respiratory motion to reduce smearing due to breathing and improve quantitation of 18F-FDG uptake in lung lesions...
  62. ncbi The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma
    Irene A Burger
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA
    Eur J Nucl Med Mol Imaging 40:701-7. 2013
    ....
  63. ncbi Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
    John P Leonard
    Department of Medicine, Division of Hematology Oncology, Weill Cornell Medical College, New York, NY, USA
    Blood 119:4597-607. 2012
    ..This study is registered at www.clinicaltrials.gov under identifier NCT00420056...
  64. ncbi The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery
    Darko Pucar
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Urol 18:87-97. 2008
    ..The aim of this article is to review novel MRI and nuclear medicine methods for detecting and planning salvage treatment for prostate cancer local recurrence after radical prostatectomy or radiation therapy...
  65. ncbi Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer
    Andrea B Apolo
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 28:3973-8. 2010
    ..This study investigated the value of FDG-PET/CT imaging in the management of patients with advanced bladder cancer...
  66. ncbi Radionuclide techniques for identifying vulnerable plaque
    Mark P S Dunphy
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 48:1753-5. 2007
  67. ncbi Advances in positron emission tomography applications for urologic cancers
    Steven M Larson
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Urol 18:65-70. 2008
    ..This review introduces the concept of molecular imaging and summarizes current and future molecular imaging approaches that are likely to have a major impact on clinical practice in the near future...
  68. ncbi Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging
    Tony Abraham
    Department of Nuclear Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA
    Semin Nucl Med 41:121-38. 2011
    ..Thyroid cancer is not a monolithic disease, and different stages and histologic entities require different approaches in imaging and individualized therapy...
  69. ncbi Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy
    Cherry L Estilo
    D Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Oncologist 13:911-20. 2008
    ..Clinical outcomes of patients with ONJ were variable with 11 patients demonstrating improvement or healing with conservative management. Our ONJ experience is presented here...
  70. ncbi Coronary artery disease after radiation therapy for Hodgkin's lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients
    Jurgen Rademaker
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1270 York Ave, New York, NY 10021, USA
    AJR Am J Roentgenol 191:32-7. 2008
    ....
  71. ncbi Identification of chondrocyte proliferation following laser irradiation, thermal injury, and mechanical trauma
    Brian J F Wong
    Beckman Laser Institute and Medical Clinic, University of California Irvine, 1002 Health Sciences Road East, Irvine, CA 92612, USA
    Lasers Surg Med 37:89-96. 2005
    ....